EUVIMEDEUVIMED entdecken
Crossref

Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow

Nihanthy D Sreenath iD, Kinjal Singh iD, Sameer Rastogi iD, Niranjan Biswal, Akash Singh iD, Adarsh Barwad iD, Asit Ranjan Mridha iD, Shivanand Gamanagatti, Shamim Ahmed Shamim iD, Yamini Dharmashaktu iD, Charu Bahl, Aparna Natrajan und 3 weitere

JCO Global Oncology · 2026-03 · 12 (3)

DOI: 10.1200/go-25-00440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2026-03. Verfasst von Nihanthy D Sreenath und 14 weiteren Autor:innen. Beteiligte Einrichtung: Saroj Gupta Cancer Centre and Research Institute, Kolkata, India. Hauptthemen laut MEDLINE: Sarcoma, High-Throughput Nucleotide Sequencing, Sequence Analysis, RNA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Sarcomas exhibit clinicopathologic heterogeneity, leading to diagnostic and therapeutic uncertainty. This study assesses the clinical value of integrating targeted RNA-based next-generation sequencing (NGS) into a multidisciplinary sarcoma workflow to improve diagnosis, enable comprehensive molecular characterization, and inform personalized treatment strategies. METHODS In this prospective single-center study, 68 patients with suspected or confirmed soft tissue sarcoma underwent RNA-based NGS using a 138-gene fusion panel, integrated within a multidisciplinary sarcoma framework. Genomic findings integrated with histopathology and immunohistochemistry for diagnostic reclassification and treatment changes. RESULTS Of 70 patients advised RNA-based NGS, 68 (97.1%) were evaluable (median age, 38.5 years). Soft tissue sarcomas predominated (77.1%), with 67.1% presenting with advanced disease. Initial histology included 17 round cell sarcomas (RC), 19 undifferentiated sarcomas (US), and 34 other subtypes. Among evaluable RC cases (n = 16), NGS identified diagnostic fusions in 87.5%, enabling reclassification in 68.7% and treatment change in 18.7%. In US, fusions were detected in 21.1%, all reclassified, with treatment altered in 75%. In other subtypes, fusions were found in 48.4%, enabling reclassification in 39.3% and treatment impact in 21.2%. Nondiagnostic mutations (eg, TP53 , SLX4 , NF1 ) were observed in 47.4% of US and 18.2% of other subtypes. Potentially actionable variants ( KIT , PIK3CA ) were seen in 5.8%. Overall, RNA-NGS was clinically informative in 50%, refined diagnosis in 41.1%, and influenced treatment in 26.4% of patients. CONCLUSION To our knowledge, this first-of-its-kind study highlights the clinical utility of integrating targeted RNA-based NGS into multidisciplinary sarcoma care, enabling diagnostic reclassification in 41.1% of cases most notably in round cell sarcomas with atypical morphology. Both canonical and rare fusions informed individualized therapy, reinforcing RNA-NGS as a pivotal tool for diagnostic refinement and precision oncology in sarcoma management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaHigh-Throughput Nucleotide SequencingSequence Analysis, RNAHumansFemaleMaleAdultProspective StudiesMiddle AgedWorkflowYoung AdultAdolescentAged

Autor:innen und Institutionen

  • Saroj Gupta Cancer Centre and Research Institute, Kolkata, India.
  • Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Radio-diagnosis, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • MedGenome Labs Ltd, Bengaluru, Karnataka, India.

ORCID-Profile: Nihanthy D Sreenath, Kinjal Singh, Sameer Rastogi, Akash Singh, Adarsh Barwad, Asit Ranjan Mridha, Shamim Ahmed Shamim, Yamini Dharmashaktu, Ekta Dhamija, Bharat Rekhi, Stanzin Spalkit

Zitieren

APA

Sreenath, N. D., Singh, K., Rastogi, S., Biswal, N., Singh, A., Barwad, A., Mridha, A. R., Gamanagatti, S., Shamim, S. A., Dharmashaktu, Y., Bahl, C., Natrajan, A., Dhamija, E., Rekhi, B., & Spalkit, S. (2026). Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow. JCO Global Oncology, 12(3). https://doi.org/10.1200/go-25-00440

Vancouver

Sreenath ND, Singh K, Rastogi S, Biswal N, Singh A, Barwad A, et al. Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow. JCO Global Oncology. 2026;12(3). doi:10.1200/go-25-00440

BibTeX
@article{Sreenath2026,
  author = {Sreenath, Nihanthy D and Singh, Kinjal and Rastogi, Sameer and Biswal, Niranjan and Singh, Akash and Barwad, Adarsh and Mridha, Asit Ranjan and Gamanagatti, Shivanand and Shamim, Shamim Ahmed and Dharmashaktu, Yamini and Bahl, Charu and Natrajan, Aparna and Dhamija, Ekta and Rekhi, Bharat and Spalkit, Stanzin},
  title = {Clinical Impact of Integrating RNA-Based Next-Generation Sequencing Into the Diagnostic Evaluation of Soft Tissue Sarcomas: Insights From a Single-Center Multidisciplinary Workflow},
  journal = {JCO Global Oncology},
  year = {2026},
  volume = {12},
  number = {3},
  doi = {10.1200/go-25-00440}
}
Kostenlos starten →